This preview shows pages 1–2. Sign up to view the full content.
This preview has intentionally blurred sections. Sign up to view the full version.View Full Document
Unformatted text preview: Optiscan Imaging Limited An Overview of the Company and its Products About Optiscan Optiscan is an Australian company that has developed and patented miniaturised confocal microscopes, and is now a global leader in the development and application of microscopic imaging technologies for medical markets. Optiscan is listed on the Australian Stock Exchange (OIL). Confocal microscopes and the Optiscan Technology Confocal microscopes are powerful laser scanning microscopes that provide high resolution, high magnification images of specimens. They can provide magnification of more than 1000 times, compared to conventional magnification in the order of 10 to 20 times. Optiscans unique and patented technology has miniaturised the microscopes scanning head, such that it is now so small it can fit inside the body. This breakthrough technology creates a vast array of new applications, both medical and industrial. Optiscans primary focus is in the medical arena, where it can provide a virtual biopsy, potentially revolutionising current pathology and histology practices. Company Background Optiscan was formed in 1994 to further advance the confocal microscope research and development activities being undertaken at that time by founders, Martin Harris and Peter Delaney. The company was listed on the Australian Stock Exchange in August 1997 to provide funding for development of a miniaturised scanner. In 1999, the company produced a world first hand held confocal microscope in prototype form. During 2000, the design was integrated into a hand held scanner for dermatology, called the Stratum, which was released to the market following regulatory clearance from the FDA in May 2001. In late 2001, Optiscan achieved further miniaturised its scanner technology, and developed a prototype scanner so small it was capable of use in an endoscope, inside the body. This world first achievement led to negotiations with leading endoscope manufacturers, and resulted in an agreement in February 2002 with Pentax, who paid US$10 million for the exclusive rights in the field of flexible endoscopy....
View Full Document
- Spring '08